홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Diisopropylethylamine → [4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(propane-2-sulfonyl)-piperazin-1-yl]-methanone

HRID 31509
인쇄

반응식

HRID 31509 반응식
[CH3:1][CH:2]([S:4]([N:7]1[CH2:12][CH2:11][NH:10][CH2:9][CH2:8]1)(=[O:6])=[O:5])[CH3:3].[Cl:13][C:14]1[CH:19]=[CH:18][C:17]([CH:20]2[CH:24]([C:25]3[CH:30]=[CH:29][C:28]([Cl:31])=[CH:27][CH:26]=3)[N:23]([C:32](Cl)=[O:33])[C:22]([C:35]3[CH:40]=[CH:39][C:38]([C:41]([F:44])([F:43])[F:42])=[CH:37][C:36]=3[O:45][CH2:46][CH3:47])=[N:21]2)=[CH:16][CH:15]=1.C(N(C(C)C)CC)(C)C>C(Cl)Cl.O>[Cl:13][C:14]1[CH:19]=[CH:18][C:17]([CH:20]2[CH:24]([C:25]3[CH:26]=[CH:27][C:28]([Cl:31])=[CH:29][CH:30]=3)[N:23]([C:32]([N:10]3[CH2:9][CH2:8][N:7]([S:4]([CH:2]([CH3:1])[CH3:3])(=[O:5])=[O:6])[CH2:12][CH2:11]3)=[O:33])[C:22]([C:35]3[CH:40]=[CH:39][C:38]([C:41]([F:42])([F:43])[F:44])=[CH:37][C:36]=3[O:45][CH2:46][CH3:47])=[N:21]2)=[CH:16][CH:15]=1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 81531DiisopropylethylamineHCID 225628511-(Isopropylsulfonyl)piperazineHCID 597928204,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride

생성물 1

HCID 11227800[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(propane-2-sulfonyl)-piperazin-1-yl]-methanone

시약·촉매·용매 2

HCID 962
Water
용매
HCID 6344Dichloromethane용매3회

실험 절차

1-(Propane-2-sulfonyl)-piperazine (0.0286 mmol) was dissolved in 0.25 mL of methylene chloride and added to a solution of 4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride (0.024 mmol, example 3) and diisopropylethylamine (0.072 mmol) in. 25 mL of methylene chloride in a 4 mL vial. The vial was capped and shaken overnight at room temperature. The reaction mixture was diluted with 1 mL of methylene chloride and 1 mL of water. The vial was agitated and centrifuged. The organic layer was transferred to a 4 mL vial and concentrated in vacuo to give [4,5-bis-(4-chloro-phenyl)-2-(2-ethoxy-4-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(propane-2-sulfonyl)-piperazin-1-yl]-methanone. LR-MS (M+H)+=697.4.

후처리

  1. customThe vial was capped
  2. stirringThe vial was agitated
  3. concentrationconcentrated in vacuo

출처 및 근거

ORD 기록
ord-eefe5043e22444d490a21d90346e8de5
출처 데이터셋
uspto-grants-2008_09
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07425638B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트